Use of NovoSeven® in Active Variceal Bleeding
Effectiveness and Safety of Use of NovoSeven® in the Treatment of Active Variceal Bleeding in Patients With Advanced Cirrhosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Wien, Austria, A 1090
- Novo Nordisk Investigational Site
-
-
-
-
-
Olomouc, Czech Republic, 77520
- Novo Nordisk Investigational Site
-
Prague 4, Czech Republic, 140 21
- Novo Nordisk Investigational Site
-
Praha 2, Czech Republic, 12821
- Novo Nordisk Investigational Site
-
-
-
-
-
Århus, Denmark, 8000
- Novo Nordisk Investigational Site
-
-
-
-
-
Helsinki, Finland, 00029 HUS
- Novo Nordisk Investigational Site
-
-
-
-
-
ANGERS cedex 09, France, 49033
- Novo Nordisk Investigational Site
-
Caen, France, 14033
- Novo Nordisk Investigational Site
-
Clichy, France, 92 188
- Novo Nordisk Investigational Site
-
GRENOBLE cedex, France, 38043
- Novo Nordisk Investigational Site
-
LIMOGES cedex, France, 87042
- Novo Nordisk Investigational Site
-
Lille, France, 59037
- Novo Nordisk Investigational Site
-
MARSEILLE cedex 05, France, 13385
- Novo Nordisk Investigational Site
-
NANTES cedex 1, France, 44093
- Novo Nordisk Investigational Site
-
NICE cedex 3, France, 06202
- Novo Nordisk Investigational Site
-
Paris, France, 75013
- Novo Nordisk Investigational Site
-
Paris, France, 75012
- Novo Nordisk Investigational Site
-
TOULOUSE cedex, France, 31059
- Novo Nordisk Investigational Site
-
Villejuif, France, 94804
- Novo Nordisk Investigational Site
-
-
-
-
-
Berlin, Germany, 13353
- Novo Nordisk Investigational Site
-
Heidelberg, Germany, 69120
- Novo Nordisk Investigational Site
-
Leipzig, Germany, 04103
- Novo Nordisk Investigational Site
-
München, Germany, 81377
- Novo Nordisk Investigational Site
-
Münster, Germany, 48145
- Novo Nordisk Investigational Site
-
Ulm, Germany, 89081
- Novo Nordisk Investigational Site
-
-
-
-
-
Shatin, Hong Kong, 32
- Novo Nordisk Investigational Site
-
-
-
-
-
Milano, Italy, 20162
- Novo Nordisk Investigational Site
-
Napoli, Italy, 80131
- Novo Nordisk Investigational Site
-
Palermo, Italy, 30146
- Novo Nordisk Investigational Site
-
-
-
-
-
Katowice, Poland, 40-752
- Novo Nordisk Investigational Site
-
Krakow, Poland, 31-826
- Novo Nordisk Investigational Site
-
Warszawa, Poland, 02-097
- Novo Nordisk Investigational Site
-
-
-
-
-
Badalona, Spain, 08916
- Novo Nordisk Investigational Site
-
Barcelona, Spain, 08036
- Novo Nordisk Investigational Site
-
Barcelona, Spain, 08003
- Novo Nordisk Investigational Site
-
Barcelona, Spain, 08025
- Novo Nordisk Investigational Site
-
Córdoba, Spain, 14004
- Novo Nordisk Investigational Site
-
Madrid, Spain, 28034
- Novo Nordisk Investigational Site
-
Madrid, Spain, 28007
- Novo Nordisk Investigational Site
-
Majadahonda, Spain, 28222
- Novo Nordisk Investigational Site
-
-
-
-
-
Taipei, Taiwan, 112
- Novo Nordisk Investigational Site
-
-
-
-
-
Leeds, United Kingdom, LS9 7TF
- Novo Nordisk Investigational Site
-
London, United Kingdom, WC1 6HX
- Novo Nordisk Investigational Site
-
Oxford, United Kingdom, OX3 9DU
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Variceal bleeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Treatment failure
Time Frame: Within 5 days after first trial product administration
|
Within 5 days after first trial product administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Mortality
|
|
Rebleeding
|
|
Control of acute bleeding
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- F7LIVER-1533
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.